AdWiki Webring Site
| SELECT YOUR LANGUAGE:
ar  |
id  |
bg  |
ca  |
ceb  |
cs  |
da  |
de  |
et  |
en  /  /  |
es  |
eo  |
fr  |
gr  |
he  |
hr  |
it  |
ko  |
lt  |
hu  |
nl  |
ja  |
no  |
pl  |
pt  |
ru  |
ro  |
sk  |
sl  |
sr  |
fi  |
sv  |
te  |
tr  |
uk  |
zh 
Mepolizumab
From Wikipedia, the free encyclopedia
Mepolizumab (marketing name Bosatria) is a humanized monoclonal antibody that recognizes the IL-5 protein. It is currently in development for the management of hypereosinophilic syndrome by GlaxoSmithKline (GSK) and has received orphan drug designation by the FDA.[1]
Previously, the drug was investigated in larger indications where eosinophils play an important role in the disease progression. Phase II trials in asthma were underway by April 1998 and by March 2002, phase II trials had also been initiated in atopic dermatitis. Mepolizumab had little efficacy in preclinical or clinical studies for atopic dermatitis [2] and it failed to sufficiently deplete eosinophils in clinical trials for asthma [3]. GSK's recent strategy has focused on gaining orphan-drug status and pursuing hypereosinophilic syndrome.
[edit] References
|
Immunomodulators – Immunosuppressants – Immunosuppressive drugs (L04) |
|
Intracellular
(signal initiation) |
|
|
| Extracellular |
|
|
|
|
|
Serum target
(noncellular)
|
|
|
|
Cellular target
|
CD3 ( Muromonab-CD3, Otelixizumab, Teplizumab, Visilizumab) · CD4 ( Clenoliximab, Keliximab, Zanolimumab) · CD11a ( Efalizumab) · CD18 ( Erlizumab) · CD20 ( Ocrelizumab, Pascolizumab) · CD23 ( Lumiliximab) · CD40 ( Teneliximab, Toralizumab) · CD62L/L-selectin ( Aselizumab) · CD80 ( Galiximab) · CD147/Basigin ( Gavilimomab, Ziralimumab) · CD154 ( Ruplizumab)
BLyS (Belimumab) · CTLA-4 (Ipilimumab, Tremelimumab) · CAT (Bertilimumab, Lerdelimumab, Metelimumab) · Integrin (Natalizumab) · Interleukin-6 receptor (Tocilizumab) · LFA-1 (Odulimomab)
IL-2 receptor/CD25 (Basiliximab, Daclizumab, Inolimomab)
T-lymphocyte ( Zolimomab aritox)
|
|
|
Unsorted
|
Atlizumab, Atorolimumab, Cedelizumab, Dorlimomab aritox, Dorlixizumab, Fontolizumab, Gantenerumab, Gomiliximab, Lebrilizumab, Maslimomab, Morolimumab, Pexelizumab, Reslizumab, Rovelizumab, Siplizumab, Talizumab, Telimomab aritox, Vapaliximab, Vepalimomab
|
|
|
|
|
|
|
|
|
|
|
|
|
Intracellular
(signal reception) |
|
|
|
Humanized monoclonal antibodies ("-zu-") |
|
| "-tuzu-" (tumor) |
Afutuzumab, Alemtuzumab, Bevacizumab/ Ranibizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Citatuzumab bogatox, Claretuzumab tetraxetan*, Clivatuzumab tetraxetan*, Dacetuzumab, Elotuzumab†, Etaracizumab, Farletuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab†, Milatuzumab, Nimotuzumab, Pamtuzumab tetraxetan*, Pertuzumab, Sibrotuzumab, Sontuzumab, Tacatuzumab tetraxetan, Tigatuzumab, Trastuzumab, Tucotuzumab celmoleukin, Veltuzumab
|
|
| "-lizu-" (immune system) |
immunosuppressive: Aselizumab, Atlizumab, Apolizumab, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Lebrilizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, Reslizumab, Rintalizumab*, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Vedolizumab, Visilizumab, TGN1412
non-immunosuppressive: Ibalizumab†
|
|
| "-bazu-" (bacterial) |
|
|
| "-cizu-" (cardiovascular) |
|
|
| "-nezu-"/"-neuzu-" (nervous system) |
|
|
| "-toxazu-" (toxin as target) |
|
|
| "-vizu-" (viral infections) |
|
|
| "-kinzu-" (interleukin as target) |
|
|
| *Names under consideration by the USAN Council. †Undergoing clinical trials. |
|
Change language: All |
Arabic |
Indonesian |
Bulgarian |
Catalan |
Cebuano |
Czech |
Danish |
German |
Estonian |
English / / |
Spanish |
Esperanto |
French |
Greek |
Hebrew |
Croatian |
Italian |
Korean |
Lithuanian |
Hungarian |
Flemish / Dutch |
Japanese |
Norwegian |
Polish |
Portugues |
Russian |
Romanian |
Slovakian |
Slovenian |
Serbian |
Suomi / Finish |
Swedish |
Iranian |
Turkish |
Ukrainian |
Chinese
MORE LINKS...
Autorem skryptu AdWiki v0.62 (2007) jest husky83
Licencję na skrypt dla strony DAWAJ.INFO posiada dzankes
Wikipedia® jest zarejestrowanym znakiem towarowym Wikimedia Foundation |
